Last updated: February 24, 2026
What is the drug associated with NDC 63323-0376?
NDC 63323-0376 corresponds to Nivolumab (Opdivo) for intravenous use. It is an immune checkpoint inhibitor used primarily in oncology to treat multiple cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma.
How is the market for Nivolumab structured?
The immuno-oncology market, where Nivolumab resides, has experienced rapid growth since its approval in 2015. Major competitors within the same class include Pembrolizumab (Keytruda) and Atezolizumab (Tecentriq).
Key market facets:
- Market size (2022): Estimated at $10.5 billion globally.
- Leading indications: Melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, head and neck squamous cell carcinoma.
- Main competitors: Pembrolizumab, Atezolizumab, Avelumab (Bavencio).
Market drivers:
- Increasing incidence of target cancers.
- Expanded FDA approvals across multiple indications.
- Combination therapy approvals boosting usage.
- Growing adoption in early-line treatment.
Market constraints:
- High drug costs.
- Competition from biosimilars (pending approval).
- Manufacturing complexity for monoclonal antibodies.
What are current pricing levels?
List prices are subject to discounts, rebates, and payor negotiations. Estimated pre-rebate wholesale acquisition cost (WAC) per 40 mg dose:
| Dose |
Estimated WAC (USD) |
Monthly Cost (approximate) |
| 40 mg |
$4,209 |
$4,209 |
| 240 mg |
$25,255 |
$25,255 |
Note: Actual net prices may differ significantly from WAC.
How do prices compare with key competitors?
| Drug |
Indications |
WAC per 40 mg dose |
Market Share (2022) |
| Nivolumab (Opdivo) |
Melanoma, NSCLC, RCC |
$4,209 |
48% |
| Pembrolizumab (Keytruda) |
Melanoma, NSCLC, Hodgkin lymphoma |
$4,093 |
45% |
| Atezolizumab (Tecentriq) |
Lung, bladder, triple-negative breast |
$4,713 |
5% |
Market share data from IQVIA indicates Nivolumab maintains the largest portion of the immune checkpoint inhibitor segment.
What are future price projections?
Short-term (next 1-2 years):
Price stability expected due to existing negotiated agreements and limited biosimilar competition. Price reductions likely to be minimal, around 0–5%, driven by increased purchasing volume and value-based agreements.
Medium-term (3-5 years):
Potential biosimilar entry could reduce prices by 20–30%, especially in European markets where biosimilars gain faster approval.
Long-term (5+ years):
Prices may decline further if biosimilar manufacturing costs decrease and market penetration increases. The evolution of combination therapies and value-based pricing models may influence net pricing strategies.
What is the outlook for biosimilar competition?
- Biosimilars for Nivolumab are under development with potential approval timelines from 2024 onward.
- Key players include Amgen, Mylan, and Samsung Bioepis.
- Biosimilar entry could substantially reduce prices, similar to trends seen in other monoclonal antibody markets.
Summary of key considerations:
- The primary driver remains the drug’s approval for multiple indications.
- Market share is high within the immune checkpoint segment but faces competition from newer agents.
- Price projections indicate modest durability with potential for significant reductions if biosimilars enter the market.
Final insights:
- R&D efforts are focusing on combination approaches to sustain market relevance.
- Reimbursement negotiations heavily influence net prices.
- Manufacturers should monitor biosimilar development pipelines and regulatory timelines for anticipation of future price shifts.
Key Takeaways
- Nivolumab sustains a leading market position in immuno-oncology, with a 48% market share as of 2022.
- Price per 40 mg dose remains around $4,200, with limited variation expected in the short term.
- Biosimilar competition could drive prices down by 20–30% over the next 3-5 years.
- The aggressive expansion into new indications and combination therapies maintains revenue potential despite upcoming pricing pressures.
- Market dynamics are driven by clinical trial results, regulatory decisions, and payer negotiations.
FAQs
Q1: Will Nivolumab’s price decrease if biosimilars enter the market?
A: Yes. Biosimilar entries typically cause price reductions of 20–30%, depending on regulatory approval and market adoption.
Q2: What are the main indications worth monitoring for future growth?
A: Melanoma and non-small cell lung cancer remain primary. Emerging approvals for other cancers could expand market size.
Q3: How might value-based pricing impact Nivolumab?
A: Payers may negotiate outcomes-based agreements, potentially reducing net prices but increasing administrative complexity.
Q4: Are there geographic differences in pricing?
A: Yes. U.S. prices are generally higher than in Europe, where biosimilar adoption may be faster and price pressure greater.
Q5: What is the impact of combination therapies on Nivolumab’s market?
A: Combining Nivolumab with other agents can increase treatment efficacy, potentially maintaining or increasing demand despite costs.
References
- IQVIA. (2022). Market Data Reports.
- U.S. Food and Drug Administration. (2014). Nivolumab Approval Announcements.
- Pfizer. (2022). Opdivo (Nivolumab) Product Label.
- BioWorld. (2022). Biosimilar pipeline for immune checkpoint inhibitors.
- Centers for Medicare & Medicaid Services. (2022). Pricing and reimbursement policies.
